Shikonin sensitizes wild-type EGFR NSCLC cells to erlotinib and gefitinib therapy

As patients with non-small cell lung cancer (NSCLC) and wild-type epidermal growth factor receptor (EGFR) are resistant to treatment with erlotinib or gefitinib, potential chemosensitizers are required to potentiate wild-type EGFR NSCLC cells to erlotinib/gefitinib treatment. The present study repor...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yang-Ling, Hu, Xiu, Li, Qing-Yu, Wang, Fei, Zhang, Bo, Ding, Ke, Tan, Bi-Qin, Lin, Neng-Ming, Zhang, Chong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2018
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6131653/
https://www.ncbi.nlm.nih.gov/pubmed/30106133
http://dx.doi.org/10.3892/mmr.2018.9347

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6131653/
https://www.ncbi.nlm.nih.gov/pubmed/30106133
http://dx.doi.org/10.3892/mmr.2018.9347

Ejemplares similares